Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hawthorn tincture is a traditional herbal pharmaceutical product manufactured by the Russian company Dalkhimpharm. It is an alcohol-based extract derived from the fruits or flowers of *Crataegus* species (hawthorn), which are rich in bioactive constituents such as flavonoids (e.g., hyperoside, quercetin), oligomeric proanthocyanidins, and polyphenols. The preparation is primarily used as a cardiotonic agent for the treatment of functional cardiovascular disorders, including mild heart failure (NYHA class I-II), cardiac arrhythmias such as tachycardia, and hypertension. Its mechanism of action involves increasing myocardial contractility (positive inotropic effect), improving coronary and peripheral blood circulation through vasodilation, and providing mild sedative and antioxidant effects. The product is administered orally and is part of Dalkhimpharm's established portfolio of marketed herbal medicines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hawthorn tincture.